Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-002345-42
    Sponsor's Protocol Code Number:998
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-07-22
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-002345-42
    A.3Full title of the trial
    A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with severe COVID-19
    Ensayo en fase II aleatorizado, controlado con placebo, doble ciego, multicéntrico en el que se investiga la eficacia y la seguridad de la trimodulina (BT588) como complemento al tratamiento de referencia en sujetos adultos con COVID-19 grave
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with severe COVID-19
    Ensayo en fase II aleatorizado, controlado con placebo, doble ciego, multicéntrico en el que se investiga la eficacia y la seguridad de la trimodulina (BT588) como complemento al tratamiento de referencia en sujetos adultos con COVID-19 grave
    A.3.2Name or abbreviated title of the trial where available
    ESsCOVID
    ESsCOVID
    A.4.1Sponsor's protocol code number998
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiotest AG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiotest AG
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiotest AG
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressLandsteinerstrasse 5
    B.5.3.2Town/ cityDreieich
    B.5.3.3Post code63303
    B.5.3.4CountryGermany
    B.5.4Telephone number+3493 227 5549
    B.5.6E-mailATORRES@clinic.cat
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametrimodulin
    D.3.2Product code BT588
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTrimodulin (human IgM, IgA, IgG solution)
    D.3.9.2Current sponsor codeBT588
    D.3.9.3Other descriptive nameIgM Concentrate
    D.3.9.4EV Substance CodeSUB189624
    D.3.10 Strength
    D.3.10.1Concentration unit g/ml gram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.05
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Severe Corona Virus Disease 2019 (COVID-19)
    Enfermedad grave por virus Corona 2019 (COVID-19)
    E.1.1.1Medical condition in easily understood language
    Severe COVID-19
    COVID-19 grave
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level PT
    E.1.2Classification code 10084380
    E.1.2Term COVID-19 pneumonia
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
    Los objetivos del ensayo son evaluar la eficacia y la seguridad de la trimodulina como complemento al tratamiento de referencia (TR) comparado con el tratamiento con placebo en sujetos adultos hospitalizados con COVID-19 grave.
    E.2.2Secondary objectives of the trial
    Pharmacodynamic (PD) and pharmacokinetic (PK) properties of trimodulin will be evaluated in all subjects.
    Se evaluarán las propiedades farmacodinámicas (FD) y farmacocinéticas (FC) de la trimodulina en todos los sujetos.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements.
    2. Male or female subject ≥18 years of age.
    3. Laboratory-confirmed SARS-CoV-2 infection.
    4. Diagnosis of community-acquired severe COVID-19 within 5 days after hospital-admission, with severe defined as:
    o Need for non-invasive ventilation (NIV), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale).
    o At least one clinical respiratory parameter:
    dyspnea, respiratory frequency ≥30/min, SpO2 ≤93%, 100 mmHg < PaO2/FiO2 ≤300 mmHg, lung infiltrates >50% within 24 to 48 hours.
    o At least one measurement of C-reactive protein ≥50 mg/L within 18 hours prior to start of treatment.
    5. Subject must receive SoC treatment for COVID-19.
    1. Consentimiento informado por escrito obtenido del sujeto o del representante legal o consentimiento informado verbal o de administración debido a una situación de pandemia, en cumplimiento de todos los requisitos legales locales.
    2. Sujetos hombres o mujeres ≥18 años de edad.
    3. Infección por SARS-CoV-2 confirmada en laboratorio.
    4. Diagnóstico de COVID-19 grave adquirida en la comunidad en el plazo de los 5 días posteriores al ingreso hospitalario, donde grave se define como:
    o Necesidad de ventilación no invasiva (VNI) o tratamiento de oxígeno de alto flujo (puntuación = 5 en la escala ordinal de 9 categorías).
    o Al menos un parámetro respiratorio clínico:
    disnea, frecuencia respiratoria ≥30/min, SpO2 ≤93 %, 100 mmHg < PaO2/FiO2 ≤300 mmHg, infiltrados pulmonares >50 % en el plazo de 24 a 48 horas.
    o Al menos una medición de la proteína C reactiva ≥50 mg/l en el plazo de las 18 horas anteriores al inicio del tratamiento.
    5. El sujeto debe recibir tratamiento de referencia para la COVID-19.
    E.4Principal exclusion criteria
    2. Subjects that deteriorated to score >5 on the 9-category ordinal scale (e.g. receiving invasive mechanical ventilation (IMV), and/or extracorporeal membrane oxygenation (ECMO)) or subjects that improved to score <5 prior to randomization.
    3. Severe neutropenia (neutrophil count <500/mm³) assessed within 18 hours prior to start of treatment.
    4. Thrombocytopenia (platelet count <30,000/mm³) assessed within 18 hours prior to start of treatment.
    5. Hemoglobin <7g/dL assessed within 18 hours prior to start of treatment.
    6. Known hemolysis.
    7. Known thrombosis or thromboembolic events (TEEs) or known medical history of TEEs (e.g. cerebrovascular accidents, transient ischemic attack, myocardial infarction, pulmonary embolism, and deep vein thrombosis) within the previous 3 months or those subjects particularly at risk for TEEs (e.g. history of thrombophilia, permanent immobilization, or permanent paralysis of the lower extremities) caused by other reasons than COVID-19.
    8. Subject on dialysis or with severe renal impairment, estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² assessed within 18 hours prior to start of treatment (details in Appendix 3: Estimated Glomerular Filtration Rate).
    9. Subject with end stage renal disease (ESRD), or known primary focal segmental glomerulosclerosis (FSGS).
    10. Known severe lung diseases interfering with COVID-19 therapy (e.g. severe interstitial lung disease, cystic fibrosis, idiopathic pulmonary fibrosis, active tuberculosis, chronically infected bronchiectasis, or active lung cancer).
    11. Known decompensated heart failure (New York Heart Association class III–IV).
    12. Known pre-existing hepatic cirrhosis, severe hepatic impairment (Child Pugh C score ≥9 points), or hepatocellular carcinoma.
    13. Known intolerance to proteins of human origin or known allergic reactions to components of trimodulin.
    15. Known treatment for thorax/head/neck/hematologic malignancies in the last 12 months.
    17. Life expectancy of less than 90 days, according to the Investigator’s clinical judgment, because of medical conditions neither related to COVID-19 nor to associated medical complications.
    18. Obesity (body mass index ≥40 kg/m²), a body weight of more than 123 kg, or anorexia (body mass index <16 kg/m²).
    1. Mujeres embarazadas o en periodo de lactancia.
    2. Sujetos que se deterioraron hasta obtener una puntuación >5 en la escala ordinal de 9 categorías (por ejemplo, reciben ventilación mecánica invasiva [VMI], y/o oxigenación por membrana extracorpórea [OMEC]) o sujetos que mejoraron hasta obtener una puntuación <5 antes de la aleatorización.
    3. Neutropenia grave (recuento de neutrófilos <500/mm³) evaluada en el plazo de las 18 horas anteriores al inicio del tratamiento.
    4. Trombocitopenia (recuento de plaquetas <30 000/mm³) evaluada en el plazo de las 18 horas anteriores al inicio del tratamiento.
    5. Hemoglobina <7 g/dl evaluada en el plazo de las 18 horas anteriores al inicio del tratamiento.
    6. Antecedentes conocidos de hemólisis.
    7. Trombosis o acontecimientos tromboembólicos (ATE) conocidos o antecedentes médicos conocidos de ATE (p. ej., accidente cerebrovascular, accidente isquémico transitorio, infarto de miocardio, embolia pulmonar y trombosis venosa profunda) en el plazo de los 3 meses anteriores o aquellos sujetos que están especialmente en riesgo de desarrollar ATE (p. ej., antecedentes de trombofilia, inmovilización permanente o parálisis permanente de las extremidades inferiores) causados por otras razones que no sean la COVID-19.
    8. Sujeto en diálisis o con insuficiencia renal grave, tasa de filtración glomerular estimada (TFGe) <30 ml/min/1,73 m² evaluada en el plazo de las 18 horas anteriores al inicio del tratamiento (los detalles se encuentran en el Apéndice 3: Tasa de filtración glomerular estimada).
    9. Sujeto con enfermedad renal terminal (ERT), o glomeruloesclerosis focal y segmentaria (GEFS) primaria conocida.
    10. Enfermedades pulmonares graves conocidas que interfieren con el tratamiento de la COVID-19 (p. ej., enfermedad pulmonar intersticial grave, fibrosis quística, fibrosis pulmonar idiopática, tuberculosis activa, bronquiectasias infectadas crónicas o cáncer de pulmón activo).
    11. Insuficiencia cardíaca descompensada conocida (Clasificación III-IV de la New York Heart Association).
    12. Cirrosis hepática preexistente conocida, insuficiencia hepática grave (escala de Child Pugh C ≥9 puntos) o carcinoma hepatocelular.
    13. Intolerancia conocida a las proteínas de origen humano o reacciones alérgicas conocidas a los componentes de la trimodulina.
    14. Deficiencia selectiva y absoluta de inmunoglobulina A (IgA) con anticuerpos conocidos contra la IgA.
    15. Tratamiento conocido para tumores malignos de tórax/cabeza/cuello/hematológicos en los últimos 12 meses.
    16. Infección conocida por el virus de la inmunodeficiencia humana.
    17. Esperanza de vida de menos de 90 días, según el criterio clínico del investigador, a causa de afecciones médicas no relacionadas con la COVID-19 ni con complicaciones médicas asociadas.
    18. Obesidad (índice de masa corporal ≥40 kg/m²), un peso corporal de más de 123 kg, o anorexia (índice de masa corporal <16 kg/m²).
    19. Antecedentes conocidos de tratamiento inmunodepresor, que no sea el tratamiento agudo de la COVID-19 (p. ej., receptor de un trasplante, sujeto con una enfermedad autoinmunitaria).
    20. Tratamiento conocido con inmunoglobulina o con hemoderivados durante los últimos 21 días antes de la aleatorización.
    21. Participación en otro ensayo clínico intervencionista en el plazo de los 30 días anteriores a la entrada, o durante el ensayo, o participación previa en este ensayo clínico.
    22. Empleado o familiar directo de un empleado de la organización de investigación por contrato, el centro del ensayo o de Biotest.
    E.5 End points
    E.5.1Primary end point(s)
    The composite endpoint is evaluated on day 29 [+3]
    El criterio de valoración compuesto se valora el día 29 (+3)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Included in E.5.1
    Clinical deterioration rate (score =6-7) between day 6 and day 29
    28-day all-cause mortality rate (score =8) between day 1 and day 29
    Incluido en E.5.1.
    - Tasa de deterioro clínico (puntuación = 6-7) entre el día 6 y el día 29
    - Tasa de mortalidad por cualquier causa de 28 días (puntuación = 8) entre el día 1 y el día 29
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints:
    • Clinical deterioration rate (day 6-29)
    • Clinical deterioration rate (day 1-29)
    • 28-days all-cause mortality rate on day 29
    • Time to clinical deterioration (change to score 6-7, day 6-29)
    • Time to clinical deterioration (change to score 6-7, day 1-29)
    • Time to mortality (change to score =8)
    • Proportion of subjects in each of the 9-categories of the ordinal scale on days 7, 14, 21, 29
    • Time to clinical improvement to score =4 until day 29
    • Time to clinical improvement to score =3 until day 29
    • Time to recovery to score ≤2 until day 29
    • Proportion of subjects with score ≤2 on day 29
    • Days of IMV
    • Days without oxygen supply until day 29
    • Time to discontinuation from any form of oxygen supply
    • Proportion of subjects without any form of oxygen supply on day 29
    • Intensive care unit (ICU)-free days until day 29
    • Hospital-free days until day 29
    • Time to SARS-CoV-2 negative status

    Secondary safety endpoints:
    • Number, severity, causality, outcome, and seriousness of all adverse events (AEs), treatment-emergent AEs (TEAEs), AEs of special interest, infusional TEAEs, TEAEs that led to permanent withdrawal of IMP, and TEAEs that led to discontinuation of the trial through day 29 [+3]
    • Number of all infusion related TEAEs through day 29 [+3]
    • Number, severity, causality, and outcome of all SAEs through day 29 [+3]
    • Dose modifications (incl. reductions and changes in infusion rate)
    • Distribution and changes over time for safety and vital signs parameters, and of overall evaluation of ECG and of ECG parameters

    Secondary pharmacokinetic endpoints:
    Changes from baseline, during and after treatment:
    • Serum concentration of IgM, IgA, and IgG

    Secondary pharmaodynamic endpoints:
    Changes from baseline, during and after treatment:
    • Markers for inflammation
    • Complement factors
    • Tasa de deterioro clínico (día 6-29)
    • Tasa de deterioro clínico (día 1-29)
    • Tasa de mortalidad por cualquier causa de 28 días el día 29
    • Tiempo hasta el deterioro clínico (variación de la puntuación a 6-7, días 6-29)
    • Tiempo hasta el deterioro clínico (variación de la puntuación a 6-7, días 1-29)
    • Tiempo hasta la mortalidad (variación de la puntuación a = 8)
    • Proporción de sujetos en cada una de las 9 categorías de la escala ordinal en los días 7, 14, 21, 29
    • Tiempo hasta la mejoría clínica con una puntuación = 4 hasta el día 29
    • Tiempo hasta la mejoría clínica con una puntuación = 3 hasta el día 29
    • Tiempo hasta la recuperación con una puntuación ≤2 hasta el día 29
    • Proporción de sujetos con una puntuación ≤2 el día 29
    • Días de VMI
    • Días sin suministro de oxígeno hasta el día 29
    • Tiempo hasta la interrupción de cualquier tipo de suministro de oxígeno
    • Proporción de pacientes sin ningún tipo de suministro de oxígeno el día 29
    • Días sin unidad de cuidados intensivos (UCI) hasta el día 29
    • Días sin hospital hasta el día 29
    • Tiempo hasta el estado negativo de SARS-CoV-2
    E.5.2.1Timepoint(s) of evaluation of this end point
    Included in E.5.2
    Incluido en E.5.2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA4
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    France
    Russian Federation
    Spain
    Sweden
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 64
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Some subjects will be unable to give consent themselves. Consent can be given on their behalf by a legally authorized representative or in an emergency situation without prior consent, if in accordance with local requirements and approved by IEC.
    Algunos sujetos no podrán dar su consentimiento, puede ser dado en su nombre por un representante legalmente autorizado o en situación de emergencia sin consentimiento previo, si cumple con los requisitos locales y está aprobado por el EC.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 114
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-08-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-07-27
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2021-06-29
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 02:40:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA